Desq Long
Sign in

Company

HALOZYME THERAPEUTICS, INC.

HALO · CIK 0001159036

SEC FORM 4
$329,009.20

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 3,100 shares at $106.132 per share.

Reporting Person Posard Matthew L. · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001159036-26-000123 · filed 2026-09-17 · View filing →

SEC FORM 4
$320,484.00

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 3,000 shares at $106.828 per share.

Reporting Person Posard Matthew L. · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001159036-26-000123 · filed 2026-09-17 · View filing →

SEC FORM 4
$961,123.84

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 8,896 shares at $108.04 per share.

Reporting Person Posard Matthew L. · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001159036-26-000123 · filed 2026-09-17 · View filing →

SEC FORM 4
$435,964.00

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 4,000 shares at $108.991 per share.

Reporting Person Posard Matthew L. · Transaction Code S

Traded Sep 16, 2026 · Disclosed Sep 17, 2026

Source: SEC Form 4 · 0001159036-26-000123 · filed 2026-09-17 · View filing →

SEC FORM 4
$484,826.38

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 4,508 shares at $107.548 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 11, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$368,200.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code M) of 20,000 shares at $18.41 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code M

Traded Sep 11, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$1,660,029.77

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 15,492 shares at $107.154 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 11, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$368,200.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code M) of 20,000 shares at $18.41 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code M

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$1,561,091.06

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 14,588 shares at $107.012 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$582,228.37

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 5,412 shares at $107.581 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 10, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$368,200.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code M) of 20,000 shares at $18.41 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code M

Traded Sep 9, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$1,426,481.49

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 13,304 shares at $107.222 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 9, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$711,187.32

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 6,596 shares at $107.821 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 9, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$10,867.00

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 100 shares at $108.67 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Sep 9, 2026 · Disclosed Sep 11, 2026

Source: SEC Form 4 · 0001159036-26-000119 · filed 2026-09-11 · View filing →

SEC FORM 4
$0.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code A) of 1,161 shares at $0 per share.

Reporting Person Appelhans Dannielle · Transaction Code A

Traded Sep 1, 2026 · Disclosed Sep 2, 2026

Source: SEC Form 4 · 0001159036-26-000117 · filed 2026-09-02 · View filing →

SEC FORM 4
$368,200.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code M) of 20,000 shares at $18.41 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code M

Traded Aug 19, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$765,777.60

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 7,200 shares at $106.358 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 19, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$1,029,350.40

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 9,600 shares at $107.224 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 19, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$344,848.00

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 3,200 shares at $107.765 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 19, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$985,815.60

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 9,400 shares at $104.874 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$368,200.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code M) of 20,000 shares at $18.41 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code M

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$587,882.35

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 5,703 shares at $103.083 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$509,826.67

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 4,897 shares at $104.11 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 18, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$368,200.00

HALOZYME THERAPEUTICS, INC. (HALO)

Acquisition (code M) of 20,000 shares at $18.41 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code M

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$89,062.20

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 900 shares at $98.958 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$50,228.50

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 500 shares at $100.457 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$213,708.60

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 2,100 shares at $101.766 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$922,977.00

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 9,000 shares at $102.553 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →

SEC FORM 4
$776,115.00

HALOZYME THERAPEUTICS, INC. (HALO)

Sale of 7,500 shares at $103.482 per share.

Reporting Person Torley Helen · Officer Title PRESIDENT AND CEO · Transaction Code S

Traded Aug 17, 2026 · Disclosed Aug 19, 2026

Source: SEC Form 4 · 0001159036-26-000108 · filed 2026-08-19 · View filing →